Clinical trial
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate…
NCT00321646 · Mary-Ellen Taplin, MD, Other · Completed
Key facts
| NCT number | NCT00321646 |
|---|---|
| Title | Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy |
| Official title | A Phase II Study of Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy |
| Lead sponsor | Mary-Ellen Taplin, MD, Other |
| Collaborators | Beth Israel Deaconess Medical Center Duke University Genentech, Inc. Industry Sanofi |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Adenocarcinoma of the Prostate |
| Intervention type | Drug |
| Interventions | Bevacizumab, Docetaxel |
| Enrollment | 42 |
| Start date | Jun 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Dec 1, 2012 |
| First posted | May 4, 2006 |
| Last update posted | May 16, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: